Advanced search
Publication Cover
International Medical Case Reports Journal Volume 15, 2022 - Issue
Submit an article Journal homepage
216
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Successful Non-Operative Treatment of Enterovesical and Enterocutaneous Fistulas Due to Crohn’s Disease

Hui Li1 Department of Gastroenterology, Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-1639-6199
ORCID Icon,
Lu Xie1 Department of Gastroenterology, Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
,
Hongdi Yao2 Zhejiang Chinese Medical University School, Hangzhou, Zhejiang, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-6308-1416
ORCID Icon,
Lexing Zhang3 Department of Radiology, Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
,
Sanhong Liang1 Department of Gastroenterology, Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China
&
Wen Lyu1 Department of Gastroenterology, Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of ChinaCorrespondence[email protected]
Pages 117-124 | Published online: 29 Mar 2022

References

  • Kaimakliotis P, Simillis C, Harbord M, Kontovounisios C, Rasheed S, Tekkis PP. A systematic review assessing medical treatment for rectovaginal and enterovesical fistulae in Crohn’s disease. J Clin Gastroenterol. 2016;50:714–721. PMID: 27466166. doi:10.1097/MCG.0000000000000607
  • Schwartz DA, Maltz BE. Treatment of fistulizing inflammatory bowel disease. Gastroenterol Clin North Am. 2009;38:595–610. PMID: 19913204. doi:10.1016/j.gtc.2009.07.009
  • Panes J, Rimola J. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14:652–664. PMID: 28790453. doi:10.1038/nrgastro.2017.104
  • Engel T, Yung DE, Ma C, et al. Effectiveness and safety of Ustekinumab for Crohn’s disease; systematic review and pooled analysis of real-world evidence. Dig Liver Dis. 2019;51:1232–1240. PMID: 31202609. doi:10.1016/j.dld.2019.05.002
  • Zhang W, Zhu W, Li Y, et al. The respective role of medical and surgical therapy for enterovesical fistula in Crohn’s disease. J Clin Gastroenterol. 2014;48:708–711. PMID: 24457944. doi:10.1097/mcg.0000000000000040
  • Present DH. Urinary tract fistulas in Crohn’s disease: surgery versus medical therapy. Am J Gastroenterol. 2002;97:2165–2167. PMID: 12358227. doi:10.1111/j.1572-0241.2002.05967.x
  • Taxonera C, Barreiro-de-acosta M, Bastida G, et al. Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn’s disease. J Crohns Colitis. 2016;10:657–662. PMID: 26786982. doi:10.1093/ecco-jcc/jjw016
  • Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8:1179–1207. doi:10.1016/j.crohns.2014.04.005
  • Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021;56:53–58. PMID: 33264569. doi:10.1080/00365521.2020.1854848
  • Sampietro GM, Casiraghi S, Foschi D. Perforating Crohn’s disease: conservative and surgical treatment. Dig Dis. 2013;31:218–221. PMID: 24030229. doi:10.1159/000353373
  • Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123–1132. PMID: 16200070. doi:10.1038/ni1254
  • Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–725. PMID: 11114383. doi:10.1016/s1074-7613(00)00070-4
  • Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113:481–517. PMID: 29610508. doi:10.1038/ajg.2018.27
  • Engel T, Kopylov U. Ustekinumab in Crohn’s disease: evidence to date and place in therapy. Ther Adv Chronic Dis. 2016;7:208–214. doi:10.1177/2040622316653306
  • Armuzzi A, Ardizzone S, Biancone L, et al. Ustekinumab in the management of Crohn’s disease: expert opinion. Dig Liver Dis. 2018;50:653–660. PMID: 29610019. doi:10.1016/j.dld.2018.02.017
  • Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. PMID: 27959607. doi:10.1056/NEJMoa1602773
  • Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease–the McGill experience. J Crohns Colitis. 2014;8:1516–1522. PMID: 24996483. doi:10.1016/j.crohns.2014.06.005
  • Lee MJ, Parker CE, Taylor SR, et al. Efficacy of medical therapies for fistulizing Crohn’s disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16:1879–1892. PMID: 29374617. doi:10.1016/j.cgh.2018.01.030
  • Madarame A, Kimura H, Kunisaki R. Successful treatment with ustekinumab for enterocutaneous fistulas in Crohn’s disease. J Crohns Colitis. 2020;14:569–570. PMID: 31616911. doi:10.1093/ecco-jcc/jjz161
  • Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn disease: a double-center cohort study. Inflamm Bowel Dis. 2021;27:e37–e8. PMID: 33200769. doi:10.1093/ibd/izaa297

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.